By Fineline Cube 
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic cooperation agreement with DP Technology to establish an AI for Science (AI4S)-driven innovation model combining “scientific intelligent agents + drug intelligent discovery platform + innovative biological drug development.” The collaboration targets antibodies, antibody-drug conjugates (ADCs), and T-cell Engagers (TCEs), leveraging artificial intelligence to enhance development efficiency and innovation quality across Boan Biotech’s pipeline.
Partnership Structure
| Element | Detail |
|---|---|
| Deal Type | Strategic cooperation (AI4S-driven drug discovery) |
| Partner 1 | Boan Biotech (HKG: 6955) – biologics development & manufacturing |
| Partner 2 | DP Technology – AI for Science platform |
| Focus Areas | Antibodies, ADCs, TCEs |
| Model | “Scientific intelligent agents + drug discovery platform + novel mechanism biologics” |
| Announcement Date | 5 Mar 2026 |
Core Collaboration Pillars
| Pillar | Application | Strategic Value |
|---|---|---|
| ① Large Life Modality Models | Antibody drug development | AI-powered antibody design, optimization, and developability prediction |
| ② Computational ADC Development | ADC pipeline expansion | In silico payload-linker selection, tumor targeting optimization |
| ③ TCE Pipeline Acceleration | T-cell engager discovery | Bispecific design, T-cell affinity engineering, safety profiling |
| ④ AI4S Innovation Scenarios | Cutting-edge exploration | Novel modality identification, mechanism deconvolution |
Strategic Rationale
Boan Biotech Contributions:
- Extensive drug development experience in antibodies, ADCs, and TCEs
- Well-established industrialization and GMP manufacturing capabilities
- Clinical-stage pipeline requiring optimization and expansion
DP Technology Contributions:
- Leading AI for Science (AI4S) technology platform
- Large-scale molecular simulation and generative AI capabilities
- Proven track record in protein structure prediction and drug-target interaction modeling
Synergy Value:
- Speed: AI-driven candidate selection reduces discovery timelines by estimated 30-40%
- Quality: In silico developability assessment reduces late-stage attrition
- Novelty: AI-enabled exploration of unconventional antibody architectures and ADC payloads
Competitive Context
| Factor | Market Implication |
|---|---|
| AI4S Adoption | China biotech sector accelerating AI integration; DP Technology among leading platform providers |
| ADC/TCE Competition | Global ADC market projected $30B+ by 2030; TCEs gaining traction in solid tumors |
| Differentiation | Computational-first approach may yield best-in-class molecules vs. traditional discovery |
| Investor Focus | HKG: 6955 shares expected to benefit from AI partnership premium |
Pipeline Impact & Outlook
- Near-term: AI-optimized antibody candidates entering IND-enabling studies within 12-18 months
- Medium-term: Novel ADCs with computationally-designed linker-payload combinations targeting solid tumors
- Long-term: TCE platform addressing autoimmune and oncology indications with AI-refined specificity profiles
Forward‑Looking Statements
This brief contains forward‑looking statements regarding technology integration timelines, pipeline advancement, and competitive positioning for the Boan Biotech-DP Technology collaboration. Actual results may differ due to AI model performance, technology transfer complexity, and clinical development risks.-Fineline Info & Tech